In most affected persons, a Hymenoptera sting results in local itching and mild induration. There are some individuals, however, who additionally respond to a sting by developing sensitization manifested by the presence of venom-specific immunoglobulin E (IgE) antibodies (vsIgE) to various components of insect venoms (in honeybee venom, 12 allergens have been identified so far: Api m1 -Api m 12; in wasp venom, 5 allergens have been identified: Vesp v 1, V v 2, Vesp v 3, Vesp v5, and Ves v 6). 2 Venom sensitization is the key factor for but is not synonymous with venom allergy. Sensitization to Hymenoptera venoms may be asymptomatic (hypersensitivity not clinically relevant) or symptomatic defined as Hymenoptera--venom allergy (HVA). The asymptomatic sensitization is common and found in 9.3% to 40.7% of the general population and in 30% to 60% of beekeepers (which reflects the effect of exposition to
swellings (not only from the insect stings, but also from a variety of insect bites), which may indicate a nonallergic irritability of the skin.
Allergic reactions to stings can be local or systemic. An LLR is defined as a swelling at the sting site exceeding 10 centimeters, developing from a few minutes to several hours after the event. LLRs located on the arms or legs can be very extensive and can last for days or even weeks, limiting daily activities and physical functioning. Sometimes LLRs are accompanied by lymph node enlargement, lymphangitis, and fever. The latter symptoms have to be differentiated from serum sickness or from infections that rarely occur in patients with an LLR because the bacteriostatic qualities of Hymenoptera venoms are believed to prevent the formation of abscesses and the occurrence of infectious lymphangitis as complications following an insect sting. LLRs resulting from a sting on the head, especially in the periorbital area, can be manifested by the swelling of the eyelids, which may be confused with angioedema, which is one of the manifestations of SAR.
12,13 Largely, LLRs are mild and not dangerous, the important exception being LLRs in the oral region that may involve tongue or throat swelling and consequent upper airway obturation. The pathomechanism of an LLR involves IgE-dependent early and late-phase allergic reactions. In patients with an LLR, the risk of a SAR to a subsequent sting is low (5%-10%), being similar to the risk of a SAR in the general population. The spectrum of SARs, which are mostly IgE--mediated, is categorized by 2 classifications, each including 4 grades (TABLE 1). The classification by Mueller grades the major symptoms from mild to life-threatening events: I -urticaria, II -angioedema, III -respiratory disorders, and IV -anaphylactic shock. The other one, proposed by Ring and Messmer, characterizes the leading symptoms from the mildest (skin lesions), through not lifethreatening cardiovascular reactions, followed by sting on sensitization to insect venoms). 3-5 Only a part of venom-sensitive people develop clinical symptoms of allergic reactions, which can be large local (LLR) or systemic (SAR). LLRs are the most frequent manifestation of HVA. Most studies in adult populations report the frequency of LLRs between 5% and 15%, but some studies-even up to 26%. 1, 6, 7 Among beekeepers, the frequency of LLR ranges between 12% and 38%. 4 SARs in the course of HVA occur in 3% to 8.9% of adults. 1, 6 The prevalence of systemic symptoms of HVA is significantly higher in 2 groups of patients: beekeepers (14%-43%) and adult patients with mastocytosis. 1, 4, 8, 9 Not all HVA adult patients suffering from mastocytosis present with an equally high percentage of systemic symptoms: the highest occurs in patients with indolent systemic mastocytosis without skin lesions (ISMs [-] : 73%) and in patients with the baseline serum tryptase (bsT) level in the range from 20.4 to 29.9 μg/l. 9,10 The lowest percentage of systemic symptoms of HVA occurs in patients with systemic mastocytosis (SM) and bsT levels below 6.1 and above 191 mcg/l or in aggressive subtypes of SM (10%).
10,11 The rarest mastocytosis variant associated with HVA is cutaneous mastocytosis (CM: 0%-7%).
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Though HVA-SAR are potentially life-threatening, the reported mortality rates are low, ranging from 0.03 to 0.48 deaths per 1 000 000 persons per year. However, the mortality data may be underestimated because many deaths from stings go unrecognized or are misinterpreted. 1 Deaths are reported mainly in male adults. 1
Clinical manifestations of Hymenoptera venom allergy
and possible reactions to a subsequent sting Insect stings normally cause painful, sometimes itching and burning, local indurations not exceeding 2 to 3 centimeters in diameter. They usually disappear after a few hours but, at times, they persist for several days. Some individuals develop large grade IV cardiac arrest a defined as: <90 mmHg in subjects >17 years of age b While assessing neurological symptoms understood as altered levels of consciousness, the Glasgow scale is employed.
In such individuals, an acute allergic episode can induce plaque erosion or rupture manifesting as an acute myocardial infarction. Type III of Kounis syndrome occurs in patients with coronary disease after coronary stent implantation. Finally, the classic cardiac complication due to an insect sting is takotsubo cardiomyopathy, a nonischemic, transient, reversible left ventricular dysfunction, also known as broken heart syndrome or stress cardiomyopathy. 18 Apart from the general dangers associated with an insect sting, there is a specific one concerning pregnant women. An insect sting can cause uterine contraction, which may result in a spontaneous abortion.
The symptomatology of nonallergic reactions to insect stings, both unusual and toxic symptoms, is presented in TABLE 2. The majority of reported unusual reactions are of neurological origin and include polyradiculomyelitis with tetraparesis (as in Guillain-Barré syndrome), epileptic cramps, extrapyramidal symptoms, and ischemic episodes with permanent central nervous damage. 12, 19 Patients with Hymenoptera-venom allergy at high risk of a severe allergic reaction It is of great clinical importance to identify the risk factors that may predispose HVA individuals to develop SARs to a subsequent field sting. The following factors have been proposed as descriptive of this group: a history of a previous SAR (grade III or IV), concomitant cardiovascular diseases, treatment with anaphylactic shock, up to cardiac arrest. Most systemic reactions begin within 30 minutes after a sting. Usually, the sooner such a reaction occurs, the more severe it is. Typically, SAR symptoms subside within a few hours, but in the case of 2-phase anaphylaxis, a relapse of symptoms is possible after 6 to 11 hours in 5% of the affected individuals. 14 Hypotension accompanying a SAR is a predictive factor for 2-phase anaphylaxis.
The most severe and life-threatening scenario of HVA involves cardiovascular symptoms, for which a number of pathogenic factors can be responsible, including hypotension due to the hypovolemic shock, hypoxia, and the cardiotoxicity of mast-cell mediators released in the course of IgE-mediated reactions. Cardiovascular HVA symptoms include acute atrial flutter, atrial and ventricular fibrillation, and acute coronary syndrome in the form of myocardial infarction. Another cardiac condition that results from the concurrence of acute coronary syndromes with mastocyte activation induced by IgE (but also by non-IgE) hypersensitivity agents is Kounis syndrome. 15-17 Patients manifesting type I of Kounis syndrome have normal coronary arteries without predisposing factors for coronary artery disease. In such patients, an acute allergic challenge induces a coronary artery spasm with normal cardiac enzyme or troponin levels or a coronary spasm progressing to acute myocardial infarction with elevated cardiac enzyme and troponin levels. Patients manifesting type II of Kounis syndrome have coexisting atheromatous coronary disease. The course of HVA-induced anaphylaxis may become more severe with the use of β-blockers and ACEIs, which are common in the treatment of hypertension, IHD, and heart failure. β-blockers are perceived as drugs that may aggravate cardiovascular manifestation and inhibit the efficiency of adrenaline used in the standard management of anaphylaxis.
25 In turn, ACEIs may deepen hypotonia occurring in anaphylaxis through increasing the concentration of bradykinin (by inhibiting its degradation by ACEIs) as well as through hindering the compensatory vasoconstriction response induced by the renin-angiotensin system. The negative effect of ACEIs on the severity of anaphylactic reactions (potentialized by the concurrent use of β-blockers) has been confirmed by clinical and experimental studies. [26] [27] [28] [29] A multicenter study conducted in a group of 962 HVA patients suggested that the use of ACEIs constitutes a risk of a severe reaction to an insect sting. 28 Patients with elevated bsT level (>11.4 ng/ml) have more severe (mostly cardiovascular) symptoms and a higher risk of the occurrence of HVA symptoms after subsequent stings than those with normal bsT levels.
8-10, 28 This group includes mostly patients with ISM with and without skin lesions, patients with other forms of SM (the World Health Organization classification defines 7 variants of SM; TABLE 3), and those with monoclonal mastocyte activation syndrome (MMAS).
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MMAS, also known as the primary MC activation syndrome (MCAS) or clonal MC activation disorder, is diagnosed in patients with unexplained or recurrent anaphylaxis without skin lesions who do not fulfill the criteria for SM, have documented KIT-mutated clonal mastocytes, and usually express CD25 on bone-marrow mastocytes. 10 A remarkable association between elevated bsT levels and the occurrence of cardiovascular symptoms in HVA patients does not only suggest a higher risk of an anaphylactic reaction to a subsequent sting β-blockers and angiotensin-converting enzyme inhibitors (ACEIs), elevated bsT levels, mastocyte activation syndrome (including mastocytosis), and older age.
The major predictive factor determining the possibility of a subsequent SAR to a sting is the severity of the previous reactions: the more severe the previous reaction, the greater the risk of a subsequent reaction being of similar or higher severity. This correlation is illustrated by data from observational studies: the risk of a recurrence of severe systemic symptoms after a field sting in persons with SAR I and II ranges from 20% to 40%, while in patients with SAR III and IV, it is as high as 60% for up to 20 years of follow-up. 20 Cardiovascular diseases are also recognized as an important factor increasing the risk of severe anaphylaxis after a sting. The causative role for this mechanism is attributed to mastocyte, which is the key effector cell in anaphylaxis. Considering an increase in the density of mastocytes in the intima and adventitia of the arterial wall in patients with ischemic heart disease (IHD), a high concentration of mastocyte mediators in such a strategic place heightens the risk of a severe reaction to an allergen.
21,22 Increased numbers of mastocytes that pose a risk of potentially severe reactions to allergens concern not only patients with IHD, but also those with other cardiac diseases, such as aortic valve stenosis (in the calcified areas of human stenotic aortic valves).
23 A negative effect of cardiovascular diseases on the course of anaphylaxis is proved by the postmortem analyses of patients with HVA who died from anaphylaxis. A study analyzing 29 patients who died following an insect sting found that most of the patients had preexisting cardiovascular or lung diseases; among 12 individuals subjected to autopsy, IHD was found in 10 and cardiomyopathies in 7 (some patients had comorbidities). 24 eye ball insect sting Symptoms range from mild conjunctivitis, anterior uveitis, corneal disorders, to sudden loss of vision; local damage caused by the stinger retained in the cornea can be clinically associated with severe conjunctival injection, chemosis, marked corneal edema, and hyphema. Subsequently, partially dislocated lens, lens abscess, partial iris atrophy, cataract formation, and optic neuropathy have been noted. In the case of eyeball penetration, the allergic local allergic reaction may appear. The anterior chamber-associated immune deviation may prevent anaphylaxis and late immunological answer reaction.
TABLE 3
Testing is performed by skin prick tests with the allergen concentration at a range from 100 to 300 μg/ml. In the case of negative results, intradermal tests are performed (venom allergen solution [0.02 ml] with increasing concentrations from 0.001 to 1.0 μg/ml). 35 Venom skin tests are the most sensitive for the diagnosis of HVA. Serum-specific IgE tests should be performed using the most sensitive methods. Depending on a country, the diagnosis of HVA is an outpatient or inpatient procedure. IgE-negative patients (both negative vsIgE and skin test results) constitute less than 2% of individuals reporting a history of allergic symptoms following a Hymenoptera sting. In such cases, the in vitro basophil activation test (BAT) is recommended, which is a flow cytometry-based functional assay that assesses the degree of cell activation after exposure to a certain concentration of venom. Basophils are identified by specific markers (CCR3 + /CD3 − , CD123 + /HLA-DR − and IgE + /CD203c + ), and their activation is measured by means of monoclonal antibodies coupled to specific fluorochromes. In HVA, both specific surface activation markers CD203c and CD63 were found to have similar kinetics with the maximum expression detected after 20 minutes of allergen stimulation. 36 The first BATs performed with recombinant allergens represent an additional step forward in developing highly sensitive in vitro tests for a specific diagnosis of HVA. 37 BAT is performed only in specialized medical centers.
A common problem with an in vitro diagnosis of HVA is encountered in patients with double positive test results for bee (HBV) and wasp venom (VV), who constitute approximately 40% to 50% of all HVA cases. 38 Sometimes, this double positivity reflects true double sensitization to both HBV and VV. More often, however, it is accounted for by "false double sensitization", which is clinically irrelevant and can be based on the presence of homologous allergens both in HBV and VV (hialuronidase, dipeptylpeptydase, vitellogenin). Another cause of "false double sensitization" may be the presence of IgE antibodies directed against cross-reactive carbohydrate determinants, which are glycol-epitopes of the allergens. In this case, IgE antibodies are directed against an α-1,3-linked fucose residue of the N-glycan core found in insects and plants. 39 New diagnostic methods based on the evaluation of IgE antibodies against individual allergenic molecules of venom (component-resolved diagnosis) have led to a significant advance in distinguishing true double sensitization from irrelevant cross-reactivity. The currently available venom allergenic components, Api m1, Ves v 1, and Ves v 5, allow for a positive diagnosis of HV-allergic patients with the accuracy of 95% for VV allergy and 63% for BV allergy. Api m 3 and Api m 10 allergenic components are expected on the market soon, which should raise the sensitivity of BV diagnosis to 87.5%. 40, 41 in HVA patients with mastocytosis but also, in consequence, constitutes an obligatory indication for tryptase tests and diagnostic workup for primary mast-cell disorders in all HVA patients who present with cardiovascular symptoms and hypotonia after a sting. However, it must be stressed that in light of the recent reports, mastocyte disorders may also be suspected in patients presenting with a SAR with hypotension and showing no skin symptoms (urticaria, angioedema) irrespective of tryptase levels. 31, 32 In contrast, in patients with extremely high tryptase levels (above 191 ng/ml) and patients with an aggressive form of SM, severe systemic HVA symptoms are rare.
Elevated serum tryptase levels could be a risk factor for more severe systemic reactions and a higher mortality rate due to HVA in elderly people. 33 A correlation between a significant increase in bsT levels and aging has been documented. The reason for this phenomenon is yet unknown. Beside mastocytosis, the possible causes of higher bsT levels also include other disease states associated with older age such as acute myelocytic leukemia, myelodysplastic syndromes, hypereosinophilic syndrome associated with the FLP1L1-PDGFRA mutation, or renal insufficiency. 34 Standard diagnostic procedures in patients with a suspicion of Hymenoptera-venom allergy Diagnostic tests for HVA are limited to patients with a history of a systemic reaction to the Hymenoptera sting. There is no other indication for the diagnostic workup for HVA. Its objectives are to: 1) verify the reaction grade and make an objective assessment of symptoms (medical history, tryptase levels); 2) identify the species that caused the symptoms; 3) determine the IgE-mediated pathomechanism of the reaction; and 4) define additional risk factors.
A carefully taken medical history is most important for the correct diagnosis of HVA. It is recommended to verify the anaphylactic origin of the sting reaction by the measurement of serum tryptase levels. To do that, blood volume of about 2 ml should be collected within 15 minutes to 3 hours following the onset of symptoms. After clotting, the sample must be centrifuged and stored at -20 o C. Another blood sample should be taken again for the measurement of bsT levels after at least a few hours following the resolution of symptoms. Higher tryptase levels measured immediately after the sting as compared with bsT levels confirm anaphylaxis. High bsT levels are a risk factor for an SAR to an insect sting in the future. As mentioned above, in these patients, diagnostic procedures for mastocytosis should be performed in reference centers (bone marrow study, KIT-mutation analysis).
The aim of diagnostic procedures is to either demonstrate or exclude the presence of specific IgE to bee or vespid venoms by skin testing and serum-specific IgE tests, optimally after 3 to 6 weeks following the occurrence of an SAR.
(antihistamines, systemic corticosteroids, short--acting β 2 -agonists) are the second-line treatment in anaphylaxis.
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All individuals with a past history of an anaphylactic reaction should be instructed in the use of and equipped with an anaphylactic kit (including adrenaline autoinjector), which they should always keep handy. They should also be referred to an allergy specialist.
Who requires venom immunotherapy?
The only causative treatment of HVA is venom immunotherapy (VIT). This treatment is very effective as it reduces the risk of a recurrent SAR to about 5% in patients allergic to wasp venom and to 10% to 20% in those allergic to bee venom. 44 VIT also significantly improves the quality of life in venom--treated individuals. 45, 46 VIT is the treatment of choice in patients fulfilling both clinical and immunological criteria: a severe generalized reaction to sting in the past medical history with respiratory or circulatory symptoms or both (grade III-IV according to Mueller) and the presence of vsIgE-antibodies to the venom of the responsible Hymenoptera species (any positive result of skin prick tests or intradermal tests or vsIgE, or How to treat allergic reactions to field stings? Medical management of allergic symptoms after a sting depends on their severity. In the case of LLRs, topical therapy with a corticosteroid ointment combined with a moist dressing (applied 2-3 times daily) is recommended. For a prominent LLR, an H 1 -antyhistamine and oral corticosteroids may be necessary. In rare cases of an LLR in the oral cavity that involve local swelling, aggressive treatment (as in systemic reactions) is required. In severe SARs, it is crucial to start an intervention as soon as possible. In the case of anaphylaxis, adrenaline is a life-saving treatment. When administered intramuscularly into the anterolateral part of the quadriceps muscle, it reaches the highest blood concentration after 8 minutes. Hence, this site is recommended for adrenaline application in all age groups.
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There are no absolute contraindications for adrenaline administration during anaphylaxis. As additional measures, the patient should be laid flat with legs raised as a protection from death due to empty superior vena cava/empty ventricle syndrome, oxygen should be given (flow, 6-10 l/min) and intravenous fluids (10 ml/kg within 10 minutes) should be administered. Other medications (TABLE 4) . 47, 48 VIT is not recommended in patients with unusual, toxic, and atypical reactions. 47, 48 Moreover, it is not recommended in patients with extensive local reactions either, although in the United States, a pilot study on selected cases of desensitization of patients with this type of a reaction was published. 49 Other current contraindications to VIT according to the 2015 EAA-CI guidelines are more flexible nowadays than in the past (TABLE 5) . 50 There are 2 steps of the VIT procedure: the initial (up-dosing) phase of immunotherapy with aqueous venom extracts and the maintenance phase with aqueous or depot venom extract. The initial phase of VIT may be performed according to 4 protocols which differ with respect to the time over which the maintenance dose is reached: slow (16-20 weeks); modified rush (6-8 weeks); rush (2-3 days), and ultra-rush (3.5 hours). The standard maintenance dose is equal to 100 μg administered at scheduled intervals of 4 to 12 weeks. The maintenance dose of venom extract should be increased to 200 μg in bee keepers, in patients who did not tolerate the insect sting at a dose of 100 μg, and in subjects with systemic side effects during the maintenance phase of VIT.
In patients with confirmed double sensitization, VIT with extracts of both wasp and bee venom is recommended. VIT should be continued for 3 to 5 years. After minimum 3 years of VIT, preferably after 5 years of VIT, a decision to stop VIT should be considered. Long-term protection after termination of VIT is established in patients treated longer than 3 years. Lifelong VIT is recommended in patients with mastocytosis. 48 Although VIT is very effective, in a few percent of HVA patients, there is a possibility of the treatment's failure, the consequence of which may be recurrence of severe systemic reactions to a subsequent sting. The identified factors believed to be responsible for VIT failure include older age, coexistence of cardiovascular or pulmonary diseases, elevated bsT levels, mastocytosis, MC-related diseases, and allergic systemic reaction to venom injections. Currently, there are no laboratory tests that could confirm the efficacy of VIT. Good tolerance of filed sting or sting challenge with an insect may confirm protection achieved in the course of VIT. Sting challenges should be performed only in specialized centers according to the existing guidelines of allergy societies. 51, 52 The new possibility to assess VIT efficacy in the future may be provided by gene expression analyses. 53, 54 VIT protects almost all HVA patients from future allergic symptoms. A major problem is the
